Results 31 to 40 of about 149 (149)
Expert Perspectives on a Clinical Challenge: Hematologic Malignancies and Vasculitis
Systemic vasculitis describes a collection of rare diseases each caused by inflammation of blood vessel walls that can cause severe systemic complications [[3, 4]](#ref‐0003). The pattern of vascular inflammation and resultant damage is frequently variable and may be mimicked, or directly triggered, by infection or malignancy.
Michelle L. Robinette, Hetty E. Carraway
wiley +1 more source
IL‐31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases Abstract Background and Aims Pruritus is associated with multiple liver diseases, particularly those with cholestasis, but the mechanism remains incompletely understood.
Jun Xu+20 more
wiley +1 more source
Some aspects of the pharmacology of ibufenac, a non-steroidal anti-inflammatory agent
Abstract When given orally to animals ibufenac has a range of potencies 2 to 4 times that of aspirin. It also suppresses thurfyl nicotinate erythema in man. Like certain other analgesic-anti-inflammatory-antipyretic drugs, when administered intravenously it suppresses bradykinin-induced bronchoconstriction in the guinea-pig.
J. S. Nicholson, P. Hebborn, S. S. Adams
openaire +3 more sources
Objective The SEMAPHORE trial evaluated the efficacy and safety of tocilizumab (TCZ) in glucocorticoid (GC)‐dependent polymyalgia rheumatica (PMR). TCZ reduced GC use and disease activity at 24 weeks. This study aimed to assess relapse rates after stopping TCZ in patients achieving remission at week 24.
Baptiste Chevet+24 more
wiley +1 more source
Objectives Dotinurad is a selective urate reabsorption inhibitor that reduces serum urate levels. We compared the efficacy and safety of dotinurad with febuxostat in Chinese patients with gout. Methods This phase 3, multicentre, randomised, double‐blind, parallel‐group study randomly allocated (1:1) eligible patients with gout to receive oral dotinurad
Jia Sun+19 more
wiley +1 more source
A deleterious variant of FCHSD1 results in mTOR pathway overactivation and may cause porto‐sinusoidal vascular disorder (PSVD). The pedigree of the family demonstrated an autosomal dominant disease with variable expressivity. Whole‐genome sequencing and Sanger sequencing both validated the existence of the FCHSD1 variant and the heterozygosity of c ...
Jingxuan Shan+19 more
wiley +1 more source
Objective To evaluate the applicability of the 2016 EULAR/ACR/PRINTO macrophage activation syndrome (MAS) classification criteria in patients with Still's disease (sJIA‐SD) treated with IL‐1‐targeted therapy and to assess the incidence of MAS in this context.
Remco G.A. Erkens+14 more
wiley +1 more source
Formulation of topical non-steroidal anti-inflammatory agents [PDF]
Reversed-pahse high-performance liquid chromatographic (HPLC) methods were developed for the assay of indomethacin, its decomposition products, ibuprofen and its (tetrahydro-2-furanyl)methyl-, (tetrahydro-2-(2H)pyranyl)methyl- and cyclohexylmethyl esters. The development and application of these HPLC systems were studied.
openaire +1 more source
Expert Perspective: Diagnosis and Treatment of Castleman Disease
Summary Castleman disease (CD) is a major diagnostic challenge for Rheumatologists. Unicentric CD (UCD) involves one enlarged lymph node region whereas multicentric CD (MCD) involves multiple enlarged lymph node regions. Both UCD and MCD may exhibit a wide range of symptoms that overlap with other immune‐mediated conditions.
Luke Y.C. Chen+2 more
wiley +1 more source
Pharmacology of diferuloyl methane (curcumin), a non-steroidal anti-inflammatory agent
Abstract Some pharmacological actions of curcumin (diferuloyl methane) have been examined in rats, mice and cats. The compound possesses significant anti-inflammatory activity in acute as well as in chronic models of inflammation. It is as potent as phenylbutazone in the carrageenan oedema test but only half as potent in chronic tests ...
R C Srimal, B N Dhawan
openaire +3 more sources